statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Investors considering a purchase of Terns Pharmaceuticals Inc (TERN) stock, but tentative about paying the going market price of 6.72/share, might benefit from considering selling puts among the...

Commit To Purchase Terns Pharmaceuticals At $5, Earn 37.2% Annualized Using Options

Terns Pharmaceuticals (NASDAQ:TERN - Free Report) had its price target decreased by UBS Group from $19.00 to $18.00 in a research note released on Wednesday morning, Benzinga reports. UBS Group...

UBS Group Cuts Terns Pharmaceuticals (NASDAQ:TERN) Price Target to $18.00

Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on Terns Pharmaceuticals (TERN Research Report) on March 27 and set a price t...

Buy Rating on Terns Pharmaceuticals Amid Promising Developments in Obesity Treatment Sector

Terns Pharmaceuticals (NASDAQ:TERN  Get Free Report) had its price target reduced by equities research analysts at UBS Group from $19.00 to $18.00 in a report released on Wednesday, Benzinga...

Terns Pharmaceuticals (NASDAQ:TERN) PT Lowered to $18.00

Terns Pharmaceuticals (NASDAQ:TERN  Get Free Report) had its price objective lowered by investment analysts at JMP Securities from $17.00 to $15.00 in a research report issued on Monday...

Terns Pharmaceuticals (NASDAQ:TERN) PT Lowered to $15.00

Terns Pharmaceuticals (NASDAQ:TERN  Get Free Report) had its price objective upped by stock analysts at BMO Capital Markets from $18.00 to $19.00 in a research report issued to clients and...

Terns Pharmaceuticals (NASDAQ:TERN) PT Raised to $19.00

Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Terns Pharmaceuticals (TERN Research Report) and Spruce Biosciences...

Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and Spruce Biosciences (SPRB)

In trading on Monday, shares of Terns Pharmaceuticals Inc (TERN) crossed below their 200 day moving average of 6.58, changing hands as low as 6.30 per share. Terns Pharmaceuticals Inc...

Terns Pharmaceuticals (TERN) Shares Cross Below 200 DMA

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Terns Pharmaceuticals reports Q4 EPS (29c), consensus (29c)

Interim data from initial dose escalation cohorts from Phase 1 trial of TERN-701 (allosteric BCR-ABL) for treatment of CML expected in second half of 2024 Top-line data from Phase 1 trial...

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Watchers	1,432
52-Wk Low	$3.26
52-Wk High	$13.23

Volume	759,766.00
52-Wk High	$13.23
52-Wk Low	$3.26

TERN Terns Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals